An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Axonics to Participate in November Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Axonics, Inc. (Nasdaq: AXNX) will be participating in two investor conferences in November. The company will present at the Wolfe Research Healthcare Conference on November 14 at 12:30 p.m. Eastern Time and at the Piper Sandler Healthcare Conference on November 29 at 10:30 a.m. Eastern Time. Interested parties can access a live webcast and replay of each presentation on the Axonics investor relations website.
Positive
None.
Negative
None.
IRVINE, Calif.--(BUSINESS WIRE)--
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in November:
Event: Wolfe Research Healthcare Conference
Date: Tuesday, November 14
Presentation time: 12:30 p.m. Eastern Time
Event: Piper Sandler Healthcare Conference
Date: Wednesday, November 29
Presentation time: 10:30 a.m. Eastern Time
Interested parties may access a live webcast and replay of each presentation by visiting the Axonics investor relations website.
About Axonics
Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 2 on the 2023 Financial Times ranking of the fastest growing companies in the Americas and No. 4 on the 2022 Deloitte Technology Fast 500.
Axonics® sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary incontinence affects an estimated 28 million women and fecal incontinence affects an estimated 19 million adults. For more information, visit www.axonics.com.
axonics modulation technologies, inc is a privately-held medical device company developing an innovative neuromodulation platform based on a miniaturized rechargeable fully-implantable ipg licensed from the alfred mann foundation. the axonics sacral neuromodulation system is designed to improve the experience of both clinicians and patients suffering from urinary and fecal dysfunction.
